Success Metrics

Clinical Success Rate
92.9%

Based on 13 completed trials

Completion Rate
93%(13/14)
Active Trials
3(17%)
Results Posted
46%(6 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_2
5
28%
Ph phase_4
4
22%
Ph phase_1
5
28%
Ph phase_3
2
11%

Phase Distribution

5

Early Stage

5

Mid Stage

6

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
5(31.3%)
Phase 2Efficacy & side effects
5(31.3%)
Phase 3Large-scale testing
2(12.5%)
Phase 4Post-market surveillance
4(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.9%

13 of 14 finished

Non-Completion Rate

7.1%

1 ended early

Currently Active

3

trials recruiting

Total Trials

18

all time

Status Distribution
Active(3)
Completed(13)
Terminated(1)
Other(1)

Detailed Status

Completed13
Recruiting3
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
3
Success Rate
92.9%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (31.3%)
Phase 25 (31.3%)
Phase 32 (12.5%)
Phase 44 (25.0%)

Trials by Status

completed1372%
recruiting317%
terminated16%
unknown16%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT07465432Phase 4

Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries

Recruiting
NCT06086626Phase 2

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

Completed
NCT04335539Phase 2

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants

Completed
NCT06547554Phase 1

A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants

Completed
NCT05922124Phase 4

Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

Recruiting
NCT07004049Phase 4

Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting
NCT04215991Phase 2

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants

Completed
NCT05373615Phase 1

Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy

Completed
NCT04995835Phase 1

Cefiderocol PK in Patients on ECMO

Completed
NCT05314764Phase 4

Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis

Completed
NCT03869437Phase 2

RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI

Completed
NCT05395104Phase 1

A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants

Completed
NCT05789199

Use of Cefiderocol in the Management of Gram-Negative Infections

Completed
NCT02714595Phase 3

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

Completed
NCT03032380Phase 3

Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens

Completed
NCT03862040Phase 1

Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia

Terminated
NCT03780140

Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections

Unknown
NCT02321800Phase 2

A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections

Completed

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18